Literature DB >> 26916391

JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus.

Joerg Wenzel1, Nadine van Holt2, Judith Maier2, Maria Vonnahme3, Thomas Bieber2, Dominik Wolf3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26916391     DOI： 10.1016/j.jid.2016.02.015

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  21 in total

Review 1.  [Familial chilblain lupus : Type 1 interferonopathy with model character].

Authors:  C Fiehn
Journal:  Z Rheumatol       Date:  2017-05       Impact factor: 1.372

Review 2.  Familial Chilblain Lupus - What Can We Learn from Type I Interferonopathies?

Authors:  Christoph Fiehn
Journal:  Curr Rheumatol Rep       Date:  2017-08-26       Impact factor: 4.592

Review 3.  JAK inhibitors in dermatology: The promise of a new drug class.

Authors:  William Damsky; Brett A King
Journal:  J Am Acad Dermatol       Date:  2017-01-28       Impact factor: 11.527

Review 4.  Emerging concepts of type I interferons in SLE pathogenesis and therapy.

Authors:  Antonios Psarras; Miriam Wittmann; Edward M Vital
Journal:  Nat Rev Rheumatol       Date:  2022-09-12       Impact factor: 32.286

Review 5.  Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases.

Authors:  Massimo Gadina; Nathalia Gazaniga; Laura Vian; Yasuko Furumoto
Journal:  J Autoimmun       Date:  2017-07-01       Impact factor: 7.094

Review 6.  Interferon-directed therapies for the treatment of systemic lupus erythematosus: a critical update.

Authors:  Yashaar Chaichian; Vibeke Strand
Journal:  Clin Rheumatol       Date:  2021-01-07       Impact factor: 2.980

Review 7.  JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.

Authors:  George E Fragoulis; Iain B McInnes; Stefan Siebert
Journal:  Rheumatology (Oxford)       Date:  2019-02-01       Impact factor: 7.580

Review 8.  Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.

Authors:  Alessia Alunno; Ivan Padjen; Antonis Fanouriakis; Dimitrios T Boumpas
Journal:  Cells       Date:  2019-08-15       Impact factor: 6.600

Review 9.  Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide.

Authors:  Alessandra Soriano; Marco Soriano; Gerard Espinosa; Raffaele Manna; Giacomo Emmi; Luca Cantarini; José Hernández-Rodríguez
Journal:  Front Immunol       Date:  2020-06-03       Impact factor: 7.561

Review 10.  Nucleic Acid Immunity in the Pathogenesis of Cutaneous Lupus Erythematosus.

Authors:  Claudia Günther
Journal:  Front Immunol       Date:  2019-07-16       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.